Addressing the Challenges of Diagnosing and Managing Pediatric Multiple Sclerosis is organized by myCME.
Release Date: March 15, 2019
Expires Date: March 15, 2020
This activity is intended for healthcare professionals, specifically, neurologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, nurses and other providers involved in the care of pediatric patients with multiple sclerosis.
• 1.75 / AMA PRA Category 1 Credit(s)™
It is estimated that 3-10% of individuals with multiple sclerosis (MS) develop symptoms in childhood and adolescence. While pediatric-onset MS is thought to represent the same disease process as adult onset forms of the disease, it poses unique challenges to the treating clinician. Diagnosing pediatric MS can be difficult due to the rarity of the disease in this age group and the existence of a broad array of disease mimics. Diagnosis may also be delayed due to a lack of recognition or dismissal of symptoms early in the course of the disease. Furthermore, pediatric providers are often unfamiliar with disease modifying treatments (DMT) for multiple sclerosis, as until recently, none were FDA licensed for use in children. The recent Food and Drug Administration (FDA) licensure of fingolimod as the first agent to treat pediatric MS is a significant event for the field, highlighting a growing recognition of pediatric-onset MS and the need for efficacy and safety data on DMTs used in children.
Upon completion of this educational activity, participants should be able to:
• Describe the possible presentations of multiple sclerosis (MS) in a child including vision, motor, sensory, and bowel/bladder related syndromes.
• Identify the categories of diseases that can mimic pediatric MS including inflammatory, neoplastic, vascular, metabolic, genetic, and mitochondrial disorders.
• Cite the types of disease-modifying therapies used in pediatric MS including the routes of administration, mechanisms of action, and efficacy/safety profiles of these agents.
• Identify symptoms suggestive of new demyelinating episodes versus pseudoexacerbations and be familiar with management strategies for both.
• Perform history-taking and counseling on areas most commonly impacted by pediatric MS, such as cognition, mood, fatigue, pain, and academic achievement.